Navigation Links
Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale
Date:10/24/2011

PINE BROOK, N.J., Oct. 24, 2011 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company focused on the development of antibody therapeutics, announced today that it is initiating a new clinical study to further demonstrate the safety of Anthim (ETI-204), the company's anti-toxin in late-stage development for prevention of disease and death from exposure to inhaled anthrax. The company also announced it has successfully manufactured Anthim at commercial scale. Anthim is an anti-toxin that significantly increases survival in anthrax-infected animals and is a promising candidate for the treatment of anthrax infection in people following a biowarfare attack.

(Logo: http://photos.prnewswire.com/prnh/20090420/NY01624LOGO)

The double blind, placebo-controlled dose-escalating study will include a total of 108 healthy human subjects and is designed to collect additional safety and pharmacokinetic (PK) data on Anthim.

"Our development timeline for Anthim is right on track, and this additional safety and PK data will further prove Anthim's utility as a strong candidate for addition to the Strategic National Stockpile," said Elizabeth Posillico, PhD, President and Chief Executive Officer of Elusys. "Anthim is demonstrating the potential to deliver significant therapeutic benefit to Americans infected with anthrax in a bioterrorism emergency."

Dr. Posillico will be presenting an update on Anthim's development program at the 10th Annual BIO Investor Forum in San Francisco on October 26.

"We have successfully manufactured Anthim at commercial scale, and look forward to finalizing our commercial production process to ensure the large-scale capacity needed to deliver high quality, consistent quantities of Anthim for the long term," added James Porter, Vice President of Development and Manufacturing at Elusys.

Anthrax is a life-threatening infectious disease caused by the bacterium Bacillus anthracis and remains one
'/>"/>

SOURCE Elusys Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Elusys Awarded $68 Million Contract to Develop Anthim for Intramuscular Pre- and Post-Exposure Prophylaxis of Anthrax Infection
2. Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development
3. Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
4. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
5. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
6. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
7. CareFusion Initiates Class I Recall of EnVe Ventilators
8. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
9. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
10. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
11. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... New York , July 11, 2014 ... by Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic ... Size, Share, Growth, Trends and Forecast, 2013-2019" the global ... in 2012 and is expected to grow at a ... an estimated value of USD 36.9 billion in 2019. ...
(Date:7/10/2014)... , July 11, 2014  Major advances ... of cancer are being highlighted in a three-day ... from 10-12 July, 2014.  Renowned national and ... share best practices and exchange knowledge on modern ... accurate and efficient. The Summit ...
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Imaging has achieved proof-of-concept with the first fully automated ... CT angiography (cCTA) study. This technology, the first to ... the potential to eliminate the need for a separate ... decrease patient radiation exposure. This work in progress is ...
... Eli Lilly and Company (NYSE: LLY ) ... today the completion of Lilly,s $2 million upgrade to the ... at Argonne,s campus outside of Chicago. The APS is a ... Facility operated by Argonne. The Lilly Research Laboratories ...
Cached Medicine Technology:Rcadia's Fully Automatic Calcium Score Assessment from Coronary CTA Shows Potential to Eliminate Need for Separate Scan 2Lilly and Argonne National Laboratory Announce $2 Million Upgrade to Lilly's Beamline Capabilities 2Lilly and Argonne National Laboratory Announce $2 Million Upgrade to Lilly's Beamline Capabilities 3
(Date:7/12/2014)... (PRWEB) July 12, 2014 Demand Response ... with considerable benefits in reducing the imbalance between energy ... grid appliances have been rolled out (due to increasing ... Infrastructure (AMI). This helps in controlling residential appliances and ... growing in the North American region, and with government ...
(Date:7/12/2014)... 12, 2014 Tylenol lawsuits ( ... move forward in the federal multidistrict litigation underway ... Bernstein Liebhard LLP reports. According to a filing ... F. Stengel has ordered the deposition of a ... found that the witness’s testimony concerning the marketing ...
(Date:7/12/2014)... News) -- Burn injuries increase in the summer as people ... experts. Among those most vulnerable to these seasonal fire hazards: ... often get burned by putting their hands on the side ... burn unit at Loyola University Medical Center in Maywood, Ill., ... of ,When you play with fire, you get burned, is ...
(Date:7/12/2014)... “After my mom’s stroke, she loss the use of ... the use of his left side. Eating became a difficult task ... people like them enjoy eating again,” said an inventor, from Fayetteville, ... CAROL HALL PLATE (P C H PLATE). , The PATRICIA CAROL ... to eat for individuals who suffer from stroke, experience tremors or ...
(Date:7/12/2014)... 2014 With prom shopping reaching its ... retailer, is ready to showcase its new and trendy ... of evening dresses in its online shop. Additionally, it ... for these elegant gowns. According to the company’s sales ... July 26, 2014. , He says, “Now, worldwide ...
Breaking Medicine News(10 mins):Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Burn Injuries More Common in Summer 2Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2
... Va. (April 13, 2009) While the number of ... registry still only includes 38 percent of licensed drivers, according ... year. Yet, according to a new survey of Americans, ... even if their family disagrees. , "The number of ...
... Rx, Inc., the,pioneering force in measuring the impact of ... physicians, announces that Mark,Degatano has joined the company as ... a newly-created position that expands and,strengthens Impact Rx,s business ... his new role Degatano will lead programs at the ...
... ... April 13, 2009 -- Accept an illicit injection and the result ... Coalition for Injectable Safety. The recent death of a Bronx, NY ... her thighs and buttocks is an unfortunate and repeating pattern of incidents ...
... FARMINGDALE, N.Y., April 13 Misonix, Inc. (Nasdaq: ... medical device technology, which in Europe is used for ... health conditions, has entered into a new, three year, ... Avanco Sistemas Medicos, based in Barcarena, Portugal, for the ...
... wide today as it was in the early ,90s, study ... with lung cancer are less likely than white patients to ... Disparities in lung cancer treatments were as large in 2002 ... there have been efforts to decrease those inequalities in treatment, ...
... As all eyes turn to the health reform debate in ... of California - will urge that "everything be on the ... D.C. Mr. Bodaken will participate in a keynote panel kicking ... that begins with an address by Dora Hughes, counselor to the ...
Cached Medicine News:Health News:While majority of Americans express interest in organ and tissue donation, few register 2Health News:Impact Rx, Inc. Names Mark Degatano as Vice President, Business Development, Key Client Initiatives 2Health News:Consumer Alert: Illegal Silicone Injections Result in Death 2Health News:Consumer Alert: Illegal Silicone Injections Result in Death 3Health News:Consumer Alert: Illegal Silicone Injections Result in Death 4Health News:Misonix Announces New Distribution Agreement for Portugal 2Health News:Misonix Announces New Distribution Agreement for Portugal 3Health News:Blacks Less Likely to Get Optimal Lung Cancer Treatment 2Health News:Blue Shield of California CEO to Speak at World Health Care Congress in Washington D.C. 2
Used for traversing and exploring urethral strictures. The malleable tip can be shaped to desired configuration. The proximal end is threaded to attach to standard followers. Supplied sterile in peel...
Used to dilate the male or female urethra to treat stricture disease. Supplied sterile in peel-open packages. Intended for one-time use....
The balloon catheter is designed to pass over a previously placed .015 inch diameter wire guide included. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
Medicine Products: